Amorphous-based controlled-release gliclazide matrix system
first_published_at:July 1, 2017, midnight / date_published:July 1, 2017
Papers
-
01/07/2017 -
by
Zheng Lu,
Yonglai Yang,
Rae-Ann Covington,
Yunxia Bi,
Thomas Dürig,
Reza Fassihi
The objective of this study was to create a hydrophilic oral controlled release system (CRS) utilizing the amorphous form of gliclazide, a BCS class II compound listed in the WHO …
